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Purpose: The purpose of  this research is to investigate the impact of  capitalization of  research
and development on the valuation of  equities for listed firms in South Africa.
Design/methodology: 15 years of  financial data (2000 to 2014) was collected, and portfolios
with similar price-to-book and market size ratios were formed to find any evidence of  any post-
investment  excess  returns  and  the  association  to  the  level  of  research  and  development
investment. Portfolios were re-formed and annually ranked by their research and development
intensity relative to sales. In addition, we looked at the changes in excess returns after adjusting
the book value as a result of  capitalizing R&D expenditure, to see if  the distortion imposed by
expensing R&D contributed to the under-valuation of  firms that invest in R&D.
Findings: The  results  indicate  that  firms  that  invest  in  research  and  development  are
systematically  under-valued.  We found no evidence of  any positive association between the
post-investment excess returns and investment levels, but rather found evidence of  the glamour
stock phenomenon in highly intensive research and development firms.
Research limitations/implications: The sample data is limited to listed firms in South Africa,
and for firms with intermittently omitted R&D on their financial report, we have assumed that
such expenditure is zero for the non-disclosed period for the purpose of  capitalization and
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amortisation. Listed firms whose main focus is on building intangible assets, are relatively few,
hence our research is descriptive in nature.
Practical implications: This paper highlights the commercial significance of  valuing the long-
term benefits of  research and development. Capitalizing the development phase as afforded by
the IASB lacks standardization, and as such, inconsistencies arise in the earnings reflected on
companies’ financial statements. For investors though, highly intensive R&D firms should be
avoided as these earn negative returns.
Originality/value: The authors are not aware of  any studies showing the effect of  accounting
rules on research and development that have been conducted in South Africa, or any research
that have shown the glamour stock phenomena when investigating the impact of  capitalization
of  research and development. Thus our contribution was to provide evidence on the valuation
of  stocks for listed firms that report research and development in South Africa that may be a
result  of  the  accounting  rules.  There  is  limited  research  on  the  accounting  treatment  of
research and development in emerging markets, whose stock exchanges have been shown to not
be highly correlated with the more developed markets, hence enables investors to diversify risk.
This should motivate both managers and investors to venture beyond what the conservative
accounting treatment of  R&D has possibly instigated when valuing stocks.
Keywords: Accounting standards, Accounting treatment of  R&D, Glamour stocks, Intellectual capital, 
Stock market returns, Value relevance
Jel Codes: G14, M4, N27, O3
1. Introduction
Research and development (R&D) forms an integral part of  a firm’s intangible investments, and signals
a strengthening of  a firm’s competitiveness (Ballester, Garcia-Ayuso & Livnat, 2003; Chan, 2012; Firer
& Williams, 2003; Lev, 1999). The practice of  continuously developing and commercializing innovative
products has proven to be a lucrative strategy for industry leaders, with companies such as Disney,
Nintendo,  Microsoft  and  Apple  demonstrating  that  they  are  better  equipped  to  compete  against
disruptive innovation by continually building intellectual capital (Habtay,  2012). R&D thus plays an
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important role in stimulating innovation and economic growth, and has become critical to maintaining
a competitive advantage in contemporary economies (Anagnostopoulou, 2008; Faff, Ho, Lin & Yap,
2013; Li, 2012; Park, Chung & Kim, 2014; Sorescu, Chandy & Prabhu, 2003). The exact economic
value of  a R&D investment however, is difficult to determine, because of  the risky nature of  R&D and
the  uncertainty  of  the  future  benefit  of  a  R&D activity.  This  uncertainty  that  is  inherent  in  the
investment’s  future  financial  performance,  poses  a  dilemma  of  whether  to  expense  or  capitalize
intangible assets.
Traditionally, the accounting standards required firms to expense R&D expenditure in accordance with
both the Generally Accepted Accounting Principles (GAAP) and the International Financial Reporting
Standards (IFRS) (Bushee, 1998; Penman & Zhang, 2012; Rubera & Kirca, 2012). The International
Accounting  Standards  Board  (IASB)  now distinguishes  the  research  phase  from the  development
phase, which enables the capitalization of  the development component (Ballester et al.,  2003). The
responsibility however, is left with management to decide when to start capitalizing the development
component, and/or whether it is to their advantage to disclose developmental information as a capital
asset, or to continue to fully expense all R&D. Since earnings are inflated when R&D is expensed,
managers  may  adopt  short-term investment  behavior  to  maintain  earnings  goals.  The  continuous
practice and argument for expensing R&D lies in the inherent risk of  the investment’s future financial
performance  (Kothari,  Laguerre  & Leone,  2002;  Park  et  al.,  2014;  Penman &  Zhang,  2012).  The
expenses recorded are intended to act as expenditures utilized to generate income within the current
financial period. 
To this end, many studies have been conducted on the accounting treatment of  R&D, particularly the
value-relevance of  capitalizing R&D. Accounting information is said to be value relevant if  it has a
component that can be explained or predicted by the current value of  the stock (Barth, Beaver &
Landsman, 2001; Kimouche & Rouabhi, 2016). Thefield of  researchon the value-relevance of  R&D
has its basis in the positive theory of  accounting, which seeks to explain and predict the accounting
practices  of  firms  (Watts  &  Zimmerman,  1990).  The  focus  of  extant  research  has  been  on  the
increased value-relevance of  capitalizing R&D into a firm’s asset base rather than expensing it in the
income statement (Aboody & Lev,  1998;  Anagnostopoulou,  2008;  Kothari  et al.,  2002;  Park et  al.,
2014). This is mainly driven by the association proven in extant research between a R&D investment
and the future stock returns, as well as between the level of  R&D investment and subsequent abnormal
excess  returns  (Bhana,  2013;  Chambers,  Jennings  &  Thompson  II,  2002;  Chan,  2012;  Chan,
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Lakonishok & Sougiannis, 2001; Eberhart, Maxwell & Siddique, 2004; Lev & Sougiannis, 1996; Lev,
Sarath & Sougiannis, 2005). 
Another  reason to capitalize  R&D is  that  the  investment  is  often undertaken to improve a  firm’s
performance  beyond  the  current  accounting  period.  Thus  it  should  be  treated  like  other  capital
expenditures, which are intended to enhance the performance of  a company beyond the current period
(Damodaran, 1999; Koller, Goedhart & Wessels, 2010). Expensing R&D is therefore in conflict with
the  intended  purpose  of  a  R&D investment.  As  such,  the  resultant  financial  statement  may  not
represent the future performance of  a firm, since it does not take into consideration the dimension of
time associated with its cost, its useful life, and cash generated by R&D, which can be misleading. This
often results in a firm showing conservative earnings in some periods and aggressive earnings in other
periods (Lev, 2003), leading to the mispricing of  an asset as investors are not able to correctly estimate
the value of  the firm’s ability to generate cash flow.
The purpose of  this research therefore was to investigate the impact of  capitalization of  R&D on the
valuation of  equities for firms listed on the Johannesburg Stock Exchange (JSE) in South Africa. The
JSE is the oldest and most developed in Africa, and has demonstrated resilience in withstanding market
turbulence.  Most  of  the  research  on  the  accounting  treatment  of  R&D is  focused  on  the  more
developed markets  and other  developing markets.  33% of  the  JSE shares  however,  are  owned by
foreign  investors.  The  interest  in  emerging  markets  by  foreign  investors  is  a  result  of  their  low
correlation with the  more developed markets,  which  enables  investors  to diversify  risk  (Alagidede,
2011). The investment by foreigners in turn is expected to stimulate the country’s economic growth and
strengthen the stock market (Adam & Tweneboah, 2009).
South African firms are required by law to use the reporting framework issued by the IASB, which
allows  the  capitalization  of  the  R&D  component.  It  is  however,  still  apparent  that  most  firms
completely expense R&D as common practice (Bhana, 2013). This is possibly due to the difficulty in
applying the rules for development expenditures, or is may be a result of  the country’s reliance on
physical over intangible assets from its pre-apartheid days. South Africa though, is currently ahead of
other African countries and its BRICS partners in terms of  its domestic policies supporting global
innovation,  placing  30  out  of  56  countries  (Ezell,  Nager  &  Atkinson,  2016).  For  investment  in
intangibles to grow, and South Africa to become a competitive global player in the modern economy,
the country’s R&D reporting needs to be value relevant. 
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There is limited academic research that has been conducted in South Africa on the value relevance of
expensing R&D. Bhana’s (2013) study, which used an event study methodology, showed that investors
react to firms' R&D announcements during the period 1995 to 2009. As argued by Chambers et  al.
(2002), accounting distortions provided using evidence from trading strategies are an indication of  an
inefficient market. Thus our goal in this paper was to provide evidence on the valuation of  stocks for
listed firms that report R&D in South Africa that may be a result of  the accounting rules. This was
investigated by contrasting the excess returns of  R&D stocks to other stocks with similar price-to-book
and market size ratios to find any evidence of  any post-investment excess returns and the association to
the level of  R&D investment. In addition, we looked at the changes in excess returns after adjusting the
book value as a result of  capitalizing R&D expenditure, to see if  the distortion imposed by expensing
R&D contributed to the under-valuation of  firms that invest in R&D. The evidence collected and
analyzed indicates a systematic under-valuation of  R&D firms. This should motivate both managers
and investors to venture beyond what the conservative accounting treatment of  R&D has possibly
instigated. 
The rest of  the paper is organized as follows. In the next section we review literature on the arguments
that have been put forth for and against the capitalization of  R&D investments. This is then followed
by a discussion on the methodology adopted to investigate the impact of  not capitalizing R&D for
listed firms that reported R&D on the JSE. The results are then discussed, and we then conclude based
on the insights gathered from our results, and provide ideas for future research.
2. Literature review
2.1. A case for R&D capitalization 
Research indicates that investment in R&D is significantly associated with an increase in subsequent
market  performance,  and  this  is  even  more  apparent  in  firms  with  high  levels  of  R&D (Lev  &
Sougiannis, 1996). This corresponds to the notion that R&D expenditure leads to improved operating
performance over time, and thus, certain investors take this into consideration when valuing stocks
(Eberhart et al., 2004; Lev & Sougiannis, 1996; Pandit, Wasley & Zach, 2011). Forecasts by financial
analysts on R&D investments however, are prone to a multitude of  biases due to the nature of  their
uncertainty (Palmon & Yezegel,  2012).  R&D levels  are usually negatively correlated to the level  of
consensus between analysts’ perceptions on its future benefit (Chambers, 2011; Dinh, Eierle, Schultze
& Steeger, 2015; Faff  et al., 2013; Palmon & Yezegel, 2012). Whilst evidence suggests that analysts have
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become more effective with their assessment of  R&D, forecast errors are still positively correlated to
the level of  R&D (Chambers et al., 2002).
Among the literature that validates these excess returns, there are two groups of  studies that generally
take place: one group observes the positive correlation between the level  of  R&D investment and
future excess return;  the other  looks at  the association between the changes in  the level  of  R&D
expenditure and the observed future excess returns (Chambers et al. , 2002). Both groups however, all
point towards two common explanations for these relationships: that this phenomenon is either due to
systematic mispricing or market compensation for the extra risk attached (Lev & Sougiannis,  1996;
Chan et al., 2001). The evidence put forth is that firms with large intangible capital have a smaller book-
to-market ratio, since R&D investment is not recognized as an asset on the accounting balance sheet
(Barth, Kasznik & McNichols, 2001; Ballester  et al., 2003; Fama & French, 1993; Lev & Sougiannis,
1996; Lev  & Sougiannis,  1999). This undervaluation and the uncertainty associated with the future
performance of  a firm, is what is attributed to the subsequent increase in market performance of  firms
invested in R&D.
Firms that invest heavily in R&D are also likely to guard their competitive advantages and innovation
strategies  closely,  since  the  both  the  GAAP  and  IFRS  do  not  enforce  disclosure  on  valuable
information about these intangible assets. This protectiveness may distort information that inevitably
eludes both competitors and investors alike about the expectations on the value or efficiency of  such
R&D investment (Chan et al., 2001; Eberhart et al., 2004; García-Meca & Martínez, 2007; Lev, 2003;
Palmon & Yezegel, 2012). Beyond the accounting implications described, Aboody and Lev (1998) also
argue that the unique nature of  R&D projects hinders investors’ ability to make financial assumptions
based on other firms’ R&D outcomes. Thus, even if  markets generally react positively toward new
R&D  information  or  announcements,  the  effects  of  conservative  accounting  distortion  and
information asymmetry may lead them to initially mis-react to R&D spending, effectively causing the
capital market to act inefficiently.
2.2. A case against R&D capitalization 
There  are  some challenges  associated  with capitalizing  a  R&D investment.  Evidence  suggests  that
markets perceive the risk of  a R&D investment to be on average three times larger than an investment
on  capital  expenditure (Anagnostopoulou,  2008).  Extant  literature  also  points  towards  firms  with
higher R&D intensity having greater systematic risk than less intensive firms due to business cycle
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fluctuations (Ciftci, Lev & Radhakrishnan, 2009; Penman & Zhang, 2012). Once the R&D is complete,
the  success  of  its  commercialization is  highly  dependent  on the market  condition at  the time the
investment decision is made, and the release window. The time lapse between the two makes relegating
the mitigation of  such risk improbable (Faff  et al., 2013).
Capital risk due to the lack of  collateral from a R&D investment is also observed, where R&D firms
are more likely to have a non-optimal capital structure. Due to the uncertainty associated with such
investments, the argument is that they cannot be utilized to issue debt (Damodaran, 1999; Faff  et al.,
2013). Thus, firms cannot set R&D as collateral for debt, as over-investment in R&D can increase the
cost of  debt. This is due to the interest premium demanded by lenders for the lack of  tangible or
marketable  collateral  attached.  Excessive  capital  allocation  towards  R&D  can  also  lead  to  under-
investment in other peripheral  assets that act as an important support structure towards extracting
additional value from R&D, thus reducing the likelihood of  commercial success (Prahalad & Hamel,
1990). Therefore, management’s unwillingness to increase the cost of  capital, as well as the need to not
disclose sensitive R&D information to debt holders, further contributes to the likelihood of  reaching
an optimal capital structure – a scenario that is known to be penalized by the market (Chambers et al.,
2002; Pandit et al., 2011).
A critical issue that current innovation-driven firms have with capitalizing R&D is that they may be
discriminated against relative to other growth firms that do not invest heavily in R&D. This is because
of  the  reliance  on  price-to-book  ratio  to  drive  investment  decisions,  which  does  not  reflect  the
intellectual capital under a firm’s asset base. Furthermore, measures of  profitability such as earnings-
per-share are often higher for non-R&D growth firms, due to the GAAP reporting standards, or for
those firms choosing to expense their R&D investment (Wang, Du, Koong & Fan, 2016). Capitalizing
R&D  therefore  does  not  allow  these  firms  to  be  viewed  on  an  equal  footing.  This  results  in
management not being rewarded for their efforts for the long-term investment (Damodaran, 1999).
The focus on accounting earnings over the significant positive correlation between R&D investments
and long-term shareholder returns is thus likely destroying future profitability as managers adopt short-
term investment behaviors to maintain earning goals. The evidence of  this can be seen in a survey
conducted by Duke University, in which 80% of  the 400 sampled chief  financial officers indicated they
would ‘reduce discretionary  spending on potentially  value-creating  activities  such as  marketing  and
R&D in order to meet their short-term earnings targets’ (Koller et al., 2010, pp. 13).
To conclude, there is evidence that supports the positive association between R&D expenditure and
subsequent operating and market performance,  indicating that this  type of  intangible investment is
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likely to have future commercial benefits (Eberhart et al., 2004; Lev & Sougiannis, 1996; Pandit et a l.,
2011). However, the increasing gap in book-to-market ratios between R&D and non-R&D firms has
drawn researchers to investigate the information on the intangible value that is prone to be concealed
from investors as a result of  expensing these intangible assets. This may inhibit the market in its ability
to fully recognize the economic value that can be achieved by R&D (Chen, Cheng & Hwang, 2005). It
is due to this paradigm that a substantial amount of  research has been conducted to investigate the
increasing value-relevance of  capitalization R&D over expensing R&D.
3. Research methodology
3.1. Data
The data required for this study, firm specific operating financial data and the annualized stock prices
for the corresponding firms, was obtained from a number of  sources: Reuter’s Data Stream, INET
BFA and the Bloomberg online platforms. The annualized stock data corresponds to six month’s post
financial year-end (31st March for most firms in South Africa). This created a sufficient time-frame for
the firms’ annual financial statements to be audited and released for that year. It also provided a robust
basis  for  earnings  and  R&D  annualized  comparison,  based  on  the  estimated  release  of  publicly
available information to investors. 
The  period  under  investigation  for  the  research  was  for  the  2000  to  2014  financial  years.  This
corresponds to a period from six years after the international sanctions were officially lifted in South
Africa, enabling the country to re-enter a global economy that is increasingly intellectual-capital based,
to the latest completed financial reporting period. But since four years of  prior R&D data was needed
in order to form the correct R&D asset, the actual data collected was from 30th September 1996 to
30th September 2015. The indices collected were R&D expenditure, sales, price-to-book, market price,
and earnings before interest and tax (EBIT). 
All listed firms (R&D and non-R&D) during this period were included in the data analysis to avoid
survivorship bias. The effect of  portfolio formation (explained later) eliminated the need for all firms
to continuously exist throughout the entirety of  the sample period. Two main assumptions pertaining
to data retrieved were made. First, that the accounting reporting of  R&D across firms is consistent.
Second, for firms with intermittently omitted R&D in their report, that such expenditure is zero for the
non-disclosed period for the purpose of  capitalization and amortization.
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3.2. Data analysis
In order to determine if  the equity market systematically under-valued firms that invest in R&D, the
analysis proceeded in three phrases, using methods described by Ballester et al. (2003), Chambers et al.
(2002), Chambers (2011), Chan et al. (2001), Eberhart et al. (2004), Fama and French (1993), and Lev
and Sougiannis (1996).
3.2.1. Data preparation for analysis
The data preparation proceeded as follows for R&D firms:
• First,  5  portfolios  were  formed  by  ranking  the  listed  firms  annually  based  on  their  R&D
intensity – defined in this research as R&D expenditure relative to sales,  a commonly used
indicator of  how much resources a firm dedicates to R&D (Chan et al., 2001). A quintile is the
de  facto  quantity  utilized  in  most  observed  literature  for  ranking  equally  sized  portfolios
(Aboody  & Lev,  1998;  Ballester  et  al.,  2003;  Chan et  al.,  2001;  Ciftci  et  al.,  2009;  Lev  &
Sougiannis, 1999; Park et al., 2014). 
• Within each quintile the Fama and French (1993) size and book-to-market factors were applied.
That is, firms were further ranked and divided into quintiles based on their book-to-market
ratio and market capitalization respectively. This resulted in 25 portfolios.
A control group of  25 portfolios of  non-R&D listed firms with corresponding book-to-market and
market  capitalization was also formed,  to be utilized as  benchmarks for  expected returns  of  each
portfolio. Over the 20 year period the total number of  firms included in each portfolio ranged from
106 to 350 for non-R&D firms, and from 12 to 53 for R&D firms. 
3.2.2. Excess returns
Next, we needed to find evidence of  post-investment excess returns (Equation 1) in firms that invest in
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where Rik is the return for firm i in month k, and Rpk is the monthly return in benchmark portfolio p. The
average excess returns for each R&D and non-R&D portfolio for one/two/three consecutive years
post portfolio formation were then calculated over the period 2000 to 2014. The average book-to-
market and market capitalization of  the annually rebalanced R&D portfolios were matched to the non-
R&D portfolios. This was calculated on the date of  comparison (last trading day of  September each
year), and re-formed annually to insure up-to-date risk adjustments. Thus, the actual return of  a firm,
less  the  corresponding  average  non-R&D control  portfolio  (Rpk),  formed the  excess  return  under
investigation.
3.2.3. Excess returns of  R&D firms based on recognised R&D capital
The next step was to investigate if  investors efficiently recognize R&D investment as a capital asset.
The  book-to-market  ratio  needed  to  be  compared  to  a  fully  capitalized  R&D  as  opposed  to  an
expensed R&D asset. Under conservative accounting, firms with large R&D expenditure have small
book-to-market ratios.  Thus,  if  investors are efficient in their  valuation of  R&D, and see past  the
conservative accounting imposed in the financial statements, then they will include R&D capital in their
assessment of  a firm’s book value. Following Chambers et al. (2002), Chan et al. (2001) and Lev and
Sougiannis  (1996),  the  current  and  past  R&D  expenditure,  RDit,  was  appropriately  capitalized
(Equation 2) using a five-year twenty percent straight-line approach as follows: 
RDCit = RDit + 0.8 x RDit-1 + 0.6 x RDit-2 + 0.4 x RDit-3 + 0.2 x RDit-4 (2)
where RDCit represents the R&D capital for firm i in year t; RDit is the unamortised R&D expenditure
for firm i in year  t. The terms on the right in Equation 2 provide an estimate of  the proportion of
spending that is still productive in a given year over the past five year period. Based on the effect of  the
change in book value as a result of  recognizing R&D capital, the R&D portfolios were then formed on
the basis of  size and adjusted book-to market ratios, and the excess returns were determined again
using Equation 1. 
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4. Results and discussion
4.1.  Evidence  of  post-investment  excess  returns  and  association  to  the  level  of  R&D
investment
Table 1 shows the average excess returns (i.e.,  R&D stock returns benchmarked against non-R&D
stock returns) of  the portfolios observed at one, two, and three years post portfolio formation from
year 2000 to 2014. The first five columns report the excess average returns based on the level of  R&D
intensity. There is no evident association between the level of  R&D intensity and the excess returns
experienced. The R&D stocks however, bar the highest R&D portfolio, have, on average, experienced
abnormal  returns  above  their  benchmark  portfolios  in  the  buy-and-hold  for  two  and  three-year
scenario,  and these  are  highest  for  the  middle  portfolio.  For  the  one-year  return  period,  marginal
differences  are  observed.  These  observations  suggests  that  firms  regard  R&D  as  a  long-term
investment that is intended to create financial benefit beyond the current financial period (Damodaran,
1999; Koller et al., 2010). Investors therefore generally under-value the future returns of  a R&D stock
at the time of  investment, specifically in the long-term, which supports the notion that investors tend
to make their investment decisions based on current earnings figures, and incorrectly ignore the future
value of  current R&D expenditure (Ciftci et al., 2009). Subsequently, share prices tend to escalate when











One-year   4.5%  -8.6%   8.3%   0.4%   -9.3% -0.9% -2.7%
Two-year 23.9%   5.7% 23.9% 15.5% -20.8%  4.7%  1.8%
Three-year 37.0% 22.1% 46.5% 35.8% -37.9%  6.5%  3.8%
Average 21.8%   6.4% 26.2% 17.2% -22.7%  3.4%  1.0%
Table 1. Average excess returns of  R&D stocks from year 2000 to 2014 grouped by R&D intensity (Chan et al., 2001)
The highest R&D intensity portfolio (portfolio 5) earns substantially negative excess returns (-22.7%)
compared to the overall average of  3.4% for all R&D firms. Extant literature suggests that high R&D
stocks  tend to  be  ‘glamour stocks’.  That  is,  stocks  having  a  lower  book-to-market  ratio,  and also
historically showing lower returns (Chan et al., 2001; Damodaran, 1999; Fama & French, 1993; Koller
et al., 2010; Lev & Sougiannis, 1999). We can see from Table 2 that the book-to-market (B/M) ratios
decrease as R&D intensity increases on average, with portfolio 5 having the lowest average B/M ratio
(0.61), and portfolio 1, the highest average B/M ratio (0.88). Table 3 shows the potential impact of
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expensing R&D on book value for the six highest R&D-intensive sectors in 2014. The low book-to-
market ratios indicate investor’s expectations of  the anticipated value from the R&D investment. The
percentage change between the adjusted book value is also expressed, showing the possible distortion
that  conventional  accounting  indicators  may  impose  on investors.  Expensing  of  R&D thus  has  a
material  effect  on  the  intrinsic  value,  eluding  investors  that  specifically  target  low book-to-market
stocks. These stocks will appear to be of  a lower book value than what it should be considered at,
resulting in over-priced stocks, and hence the negative returns.
Year 1 (low R&D) 2 3 4
5 
(high R&D)
2000 0.82 1.17 0.51 0.82 0.55
2001 2.18 0.96 1.19 0.44 0.83
2002 1.02 1.11 0.86 0.83 0.42
2003 0.82 0.98 0.88 0.59 0.43
2004 1.32 0.76 0.62 0.72 0.80
2005 0.73 0.51 0.55 0.67 0.70
2006 0.48 0.59 0.48 0.48 0.56
2007 0.36 0.40 0.49 0.40 0.43
2008 0.32 0.53 0.61 0.44 0.47
2009 0.83 1.01 0.85 0.70 0.57
2010 0.97 0.89 0.64 0.71 0.57
2011 0.97 0.59 0.92 0.76 0.50
2012 1.06 1.25 0.70 0.66 0.61
2013 0.73 0.58 0.65 0.65 0.66
2014 0.61 0.61 0.52 0.63 1.11
Average 0.88 0.80 0.70 0.64 0.61
Table 2. Book-to-market ratio of  R&D stocks from year 2000 to 2014 grouped
by R&D intensity
B/M Adjusted B/M % change of  B/M
Chemical 0.46 0.47 -1.41%
Diversified Industrials 0.91 0.91 0.00%
Electrical and electronic equipment 0.95 0.96 -0.96%
Food processors 0.48 0.49 -0.97%
Industrial mining 1.08 1.10 -2.20%
Pharmaceutical 0.33 0.34 -2.69%
Table 3. The effect on book-to-market ratio from capitalising R&D for the year
2014 for high intensive R&D sectors
Thus, whilst we do not observe any apparent association between the level of  R&D investment and
post-investment excess returns, overall, R&D stocks performed better than non-R&D stocks at one,
two, and three years post portfolio formation from year 2000 to 2014, with the exception of  portfolio 5
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(highest R&D intensity). The R&D stocks also performed better on average than non-R&D stocks (last
two columns of  Table 1), an indication that the market is not fully accounting for the future benefit of
the R&D investment. The highest R&D intensity stocks (portfolio 5) are the quintessential glamour
stocks,  an indication  that  there  is  more value  in  the  lower  R&D-intensive  firms compared to  the
affluent R&D firms. As research by García-Meca  and Martínez (2007) illustrated, the use of  R&D
information by financial analysts is more prominent in profitable firms. This suggests that investors
potentially overlook the value inherent in other smaller firms undertaking R&D.
4.2. Excess returns of  R&D firms based on recognised R&D capital
The excess returns observed in Table 4, based on adjusted book-to-market ratios, indicate a similar
pattern to that  observed in Table  1.  There  is  no apparent  association between the level  of  R&D
intensity and the adjusted excess returns experienced, and the R&D stocks have, bar the highest R&D











One-year   5.8%  -8.2%  8.3%   1.0% -12.4% -1.1% -2.7%
Two-year 26.8%   4.8% 23.9% 15.5% -17.0%  5.3%  1.8%
Three-year 40.2% 22.4% 46.5% 35.8% -33.9%  6.9%  3.8%
Average 24.3%   6.3% 26.2% 17.4% -21.1%  3.7%  1.0%
Table 4. Average excess returns of  R&D stocks from year 2000 to 2014, based on adjusted
book value, grouped by R&D intensity (Chan et al., 2001)
The change in excess returns across all  portfolios, whilst mainly positive, has been relatively minor
(refer to Table 5). The most noticeable changes occur at both ends of  the R&D intensity spectrum
(portfolios 1 and 5), with portfolio 1 experiencing the most change in its excess returns at 2.5% on
average  above  the  un-adjusted  excess  returns.  This  could  be  an  indication  of  the  investors
underestimating  the  future  benefits  associated  with firms that  do not  spend heavily  on R&D. On
average however, we observe a slight increase in annualized positive excess returns (0.3%) after book-
to-market adjustment. This suggests that the market does not factor in R&D expenditure as an asset,
hence the tendency to misprice R&D stocks is indeed motivated by accounting book-value distortions.
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One-year 1.0% 0.4% 0.0% 0.6% -3.1% -0.2%
Two-year 2.9% -0.9% 0.0% 0.0%  3.8%  0.6%
Three-year 3.2% 0.2% 0.0% 0.0%  4.1%  0.4%
Average 2.5% -0.1% 0.0% 0.2%  1.6%  0.3%
Table 5. Change in excess returns of  R&D stocks from year 2000 to 2014, due to adjusted book value
grouped by R&D intensity (Chan et al., 2001)
5. Conclusion
The purpose of  this research was to determine the impact of  valuing R&D stocks on the JSE, in order
to determine if  investors price the value of  R&D expenditure into the stock price. A majority of  firms
in South Africa still choose to expense all their R&D, because historically, the country relied heavily on
labour and natural resources. Thus we wished to establish if  investors generally misprice firms that
participate in R&D, and if  the conservative accounting standards that govern how firms can report on
their R&D contributes to this mispricing. Our investigation covered the sample period from year 2000
to 2014, focusing on short-term and long-term buy-and-hold excess returns of  R&D firms for one,
two, and three years post portfolio formation. 
Our findings align with past research, indicating that firms that invest in R&D experience a noticeable
level of  positive (risk-adjusted) excess returns, and actually out-perform non-R&D stocks in the long
term. The post investment excess returns are an indication that the accounting reporting of  R&D by
firms is not fully informative across the full sample. Unlike some of  the prior studies, we did not find
evidence of  any association between the level of  R&D investment and post-investment excess returns,
but  found evidence  of  the  glamour stock  phenomenon in  highly  intensive  R&D firms.  Thus  the
returns are higher for less intensive R&D firms than for the highly intensive R&D firms. The book-to-
market ratios decrease as the level of  R&D intensity increases on average, hence the use of  accounting
indicators such as book value may be eluding investors that  specifically  target  low book-to-market
stocks,  or  those  who only  consider  R&D information in  profitable  firms.  The  findings  from this
research thus imply that potential investors should consider investing in firms that have undertaken
R&D since these earn excess (risk-adjusted) returns,  but should avoid over-pricing highly intensive
R&D firms with low book value, as these will lead to earning negative returns. Glamour stocks are
typically popular among investors, who potentially miss the value inherent in the other R&D stocks
when examining financial reports. 
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Lastly,  there  needs  to be  more consideration  in  how R&D expenditure  is  treated  in  the  financial
statements. Capitalizing the development phase as afforded by the IASB lacks standardization, and as
such, inconsistencies arise in the earnings reflected on companies’ financial statements. Other factors
such as the history of  success of  a firm with R&D, proven R&D concepts, and the riskiness of  the
asset, need to be taken into consideration, as the R&D benefit is intended for and experienced beyond
the current financial period.
There are different avenues for further research. Since South Africa is mainly a labor and commodity-
based economy, listed firms whose main focus is on building intangible assets, are relatively few, hence
the descriptive  nature of  our research.  If  the number of  listed firms were to grow in the future,
continuing the research on a more recent sample using robust methodology, as well as ensuring sector
neutrality and incorporating industry-specific capitalization rates of  the various R&D assets in future
research, could help better understand the impact of  R&D on firm value. Different market conditions
also lend themselves to varying levels of  information asymmetry (Cormier, Houle & Ledoux, 2013),
with  firms likely  to closely  guard their  competitive  advantages  and innovation strategies  when the
economy declines. The valuation of  R&D listed firms is also not immune to over-investment derived
from bullish  market  conditions.  Thus  future  research  could  compare  the  accounting  distortion  of
immediately expensing R&D during times of  crises,  a  period immediately following the crisis,  and
periods of  certainty, to determine the extent of  the distortion under the different market conditions. 
The portfolio with the highest R&D intensity actually stands out as being systematically over-valued by
investors.  Besides  the  accounting  indicators,  previous  successes  of  these  firms  may  explain  the
optimism by investors, thus another avenue for further research is to look at the relationship between
investor confidence and R&D valuation. Lower R&D intensity firms could be impacted more by sales
volatility  than  high  R&D  intensity  firms,  thus  future  research  utilising  different  R&D  intensity
definitions (e.g. R&D expenditure relative to market price or book value) may prove to be insightful.
With a larger sample, future studies could also compare and contrast the results to other developing
countries, especially since the glamour effect phenomemon is not common in these types of  research.
Finally, Gong and Wang (2016) have shown the decline in the value relevance of  R&D expenses post
the adoption of  the IFRS, thus it will also be of  interest in the future to see how long it takes for this
phenomenon to occur in South Africa.
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